Enhanced Profiles Drive BlackRock, Invesco and Boutique Managers to The Wealth Advisor's New Model Portfolio Selection Guide
October 22, 2021 14:03 ET | The Wealth Advisor
SANTA MONICA, Calif., Oct. 22, 2021 (GLOBE NEWSWIRE) -- The Wealth Advisor, a Marina Media LLC publication, today announced the upcoming launch of the first Model Portfolio & SMA Strategists:...
Biogen Responds to CADTH’s updated recommendation regarding coverage for SPINRAZA
March 01, 2019 20:18 ET | Biogen Canada
·Canadian Association of Drugs and Technologies in Health (CADTH) has expanded their recommendations for public reimbursement for SMA patients ·The recommendation, however, continues to limit access...
La réaction de Biogen aux recommandations mises à jour de l’ACMTS concernant l’accès à SPINRAZA
March 01, 2019 20:18 ET | Biogen Canada
·L’Agence canadienne des médicaments et des technologies de la santé (ACMTS) a élargi ses recommandations concernant le financement par les fonds publics du traitement des patients atteints...
PNGPIX-COM-Biogen-Logo-PNG-Transparent-500x192.png
Biogen Applauds Quebec Decision to Cover SPINRAZA™ (nusinersen) for a broad population of SMA Patients
December 20, 2018 12:19 ET | Biogen Canada
The decision follows positive recommendation from the Institut national d'excellence en santé et services sociaux (INESSS) recognising the urgency and need for a treatment for patients with SMA and...
Biogen salue la décision du Québec de rembourser SPINRAZAMC (nusinersen) pour une vaste population de patients atteints d’amyotrophie spinale (AS)
December 20, 2018 12:19 ET | Biogen Canada
MISSISSAUGA, Ontario, 20 déc. 2018 (GLOBE NEWSWIRE) -- Cette décision découle de la recommandation positive de l’Institut national d’excellence en santé et services sociaux (INESSS) qui...
Biogen_Logo_Standard-rgb_R.jpg
New SPINRAZA® (nusinersen) Data Presented at Annual Congress of the World Muscle Society Demonstrate Benefits in Treating Presymptomatic Infants with Spinal Muscular Atrophy
October 06, 2018 07:30 ET | Biogen Inc.
NURTURE study participants were alive and did not require permanent ventilation, in contrast to natural history of spinal muscular atrophy (SMA)Study participants achieved motor milestones with 100...
Vestmark_logo_indeed.png
Vestmark Announces Innovative Options Trading and Risk Management Capabilities
August 16, 2018 09:30 ET | Vestmark, Inc.
WAKEFIELD, Mass., Aug. 16, 2018 (GLOBE NEWSWIRE) -- Vestmark, the leading provider of portfolio management and trading solutions for financial advisors and institutions, today announced a new...
Spotlight Innovation Spinal Muscular Atrophy Research Collaborator Professor Kevin Hodgetts Receives $300,000 Grant from Cure SMA
July 24, 2018 08:55 ET | Spotlight Innovation Inc.
URBANDALE, IA, July 24, 2018 (GLOBE NEWSWIRE) -- Spotlight Innovation Inc. (OTCQB: STLT), a pharmaceutical company targeting rare, emerging and neglected diseases, today announced that Company...
Cytokinetics_Logo_RGB (1).jpg
Cytokinetics Announces Data From Phase 2 Clinical Study of Reldesemtiv in Patients With Spinal Muscular Atrophy Presented at the 2018 Annual Cure SMA Conference
June 16, 2018 11:40 ET | Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., June 16, 2018 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced data from the Phase 2 clinical study of reldesemtiv in patients with spinal...
Scholar Rock logo2.png
Scholar Rock Announces Completion of Dosing of First Cohort in Phase 1 Clinical Trial of SRK-015
May 31, 2018 07:00 ET | Scholar Rock
CAMBRIDGE, Mass., May 31, 2018 (GLOBE NEWSWIRE) -- Scholar Rock (NASDAQ:SRRK), a biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of...